Sundar Jagannath

39PUBLICATIONS
218CO-AUTHORS
Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|May 14, 2026
Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.

|May 08, 2026
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

|Apr 01, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.

Shaji Kumar, Katja C Weisel, Paul Spin

|Mar 30, 2026
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.

Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng

|Mar 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Shaji Kumar, Sundar Jagannath, Katja C Weisel

|Jan 21, 2026
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Melissa Alsina, Nina Shah, Sundar Jagannath

Pageof 7

Frequent Collaborators

11 joint publications

Joshua Richter

10 joint publications

Hearn Jay Cho

9 joint publications

Samir S Parekh

8 joint publications

Santiago Thibaud